The UK government tabled three amendments to the Health Bill on September 1, 2026, signaling a major overhaul of the MHRA's regulatory powers for medical devices. This episode breaks down the proposals, including new information-sharing capabilities, measures for faster regulatory updates, and enabling powers for a potential future direct-to-regulator licensing system that could replace the current UK Approved Body model. We analyze the long-term strategic implications for manufacturers and outline practical steps for regulatory and quality teams to prepare for this evolving landscape.

Key Questions:

- What are the three major amendments to the UK Health Bill affecting the MHRA?

- How will new information-sharing powers impact medical device manufacturers?

- Why is the UK government seeking to make regulations more responsive to scientific changes?

- What is the proposed future licensing regime for medical devices in the UK?

- How could this new regime replace the current Approved Body conformity assessment model?

- What was the significance of the September 1, 2026 date for these proposals?

- What practical steps should regulatory teams take in response to this legislative development?

- How does this potential shift align with other global regulatory models?

Sources:

- https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill

How Pure Global can help:

Navigating major legislative shifts like the proposed UK Health Bill amendments requires expert guidance and a forward-thinking strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Our services include regulatory strategy, continuous regulatory monitoring, and technical dossier preparation to help you anticipate and adapt to changes in over 30 markets. Let us help you maintain compliance and secure your market presence in a dynamic regulatory world. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode details the US FDA's new draft guidance on an electronic submission template for Premarket Approval (PMA) applications, issued on September 17, 2026. We explore which submission types are covered, such as Original PMAs and Panel-Track Supplements, and explain how the template aims to improve submission consistency and review efficiency for high-risk Class III medical devices. We also outline practical steps for regulatory and quality teams to prepare for this upcoming change.

Key Questions:

- What is the new FDA draft guidance on PMA electronic submissions issued in September 2026?

- Which specific PMA submission types does the new template cover?

- Why did the FDA introduce this standardized electronic template?

- How will this new template impact the review process for high-risk devices?

- What are the immediate next steps for regulatory teams preparing for a PMA submission?

- Is the use of this new electronic template mandatory?

- What are the potential benefits of adopting the template early?

- How can manufacturers provide feedback on this draft guidance?

Sources:

- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-premarket-approval-applications-pma

- https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates

- https://www.govinfo.gov/content/pkg/FR-2026-09-18/html/2026-20202.htm

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for submissions to authorities like the FDA. Our team of local experts in over 30 countries can help you navigate complex requirements, ensuring your submissions are compliant and optimized for a smooth review. Whether you're a startup or a multinational, we can streamline your path to market. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global regulatory database at https://pureglobal.ai.

This episode breaks down South Korea's Ministry of Food and Drug Safety (MFDS) Notice No. 2026-63, which details new evidence requirements for obtaining a post-market study exemption. Effective August 31, 2026, this notice affects manufacturers of new and orphan medical devices. We explain the specific criteria for demonstrating sufficient overseas use, including the required post-market clinical experience, safety information, and international sales history. This episode provides actionable guidance for regulatory and market access teams on how to leverage existing global data to meet these new standards and streamline entry into the Korean market.

Key Questions:

- What is MFDS Notice No. 2026-63 and who does it affect?

- How can manufacturers of new or orphan medical devices gain an exemption from post-market studies in South Korea?

- What specific types of overseas clinical experience data are now required?

- What safety information, including recall and adverse event data, must be submitted?

- How much international sales history is needed to satisfy the new MFDS criteria?

- What are the practical steps for compiling a successful exemption application?

- How does this change impact market access strategy for South Korea?

Sources:

- https://www.pure-global.com/insights/korea-mfds-2026-63-post-market-study-exemption-evidence/

- https://www.pure-global.com/news/

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting to help MedTech companies navigate complex market access challenges like those in South Korea. Our experts can develop a clear regulatory strategy for your device, leveraging pathways like the post-market study exemption. We use advanced AI tools to efficiently compile, manage, and submit the technical dossiers required by authorities like the MFDS, ensuring your global clinical, safety, and sales data is presented effectively. For help with your Korean market access strategy or any of our 30+ markets, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

This episode covers Health Canada's September 2, 2026, update to the forms for exceptional importation and sale of medical devices. We discuss the key changes, the criteria for using this pathway to address device shortages, and the practical steps manufacturers must take to prepare and submit successful applications.

Key Questions:

- What is Health Canada's exceptional importation pathway for medical devices?

- What specific changes were made to the application forms on September 2, 2026?

- How does a manufacturer prove a medical device shortage exists?

- What information is now required to justify the need for a non-compliant device?

- Who is eligible to apply for exceptional importation authorization?

- What are the common pitfalls to avoid when submitting an application?

- How can regulatory teams prepare for urgent shortage situations?

- What is the long-term plan required for devices imported under this rule?

Sources:

- https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. Our experts in Canada can guide you through complex pathways like the exceptional importation process, ensuring your submissions are comprehensive and meet Health Canada's clarified requirements. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative. By combining in-country expertise with advanced AI technology, we streamline compliance and help you maintain market presence. For support with your market access needs, contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

China's NMPA has released new mandatory GMP Inspection Guidance Principles, effective November 1, 2026. This episode breaks down the critical changes, including the new deficiency classification system (critical, major, and minor) and the impact on both production-license and post-market inspections. We provide practical, actionable steps for medical device manufacturers to conduct gap analyses, update internal audit programs, and prepare their quality systems for this more stringent regulatory environment to avoid enforcement actions and market access delays.

Key Questions:

- What are the key changes in China's new NMPA GMP Inspection Guidance Principles?

- When does the new guidance become mandatory for all manufacturers?

- How will NMPA inspectors classify deficiencies like critical, major, and minor findings after November 1, 2026?

- What are the potential enforcement actions for non-compliance with the new GMP standards?

- Which quality system areas are likely to face the most scrutiny during an inspection?

- How can you conduct a gap analysis of your QMS against the new Chinese requirements?

- What practical steps should your regulatory and quality teams take before the deadline?

- Why is updating your internal audit program critical for NMPA inspection readiness?

Sources:

- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGPm-E4H7oXurZrQI5Z7_vIQsf33rHuKVY9zMYXA2miH_lOgvn1BzdYI0mV-APrMtGjiDgcTqVl3-6hts5MVvV0KL6fNawp255mdWxZdixxfdcUyGQN-zIXhC7kSuxau1iimCJvoNpiUTYxoQOqdohsAHpUnGzu6qVqEOepmljQs0vdSPnvPZHkmAHVXbS

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to enter or maintain their presence in global markets like China. Our experts can help you navigate the new NMPA GMP Inspection Guidance by developing a tailored regulatory strategy, conducting a thorough gap analysis of your QMS, and assisting with technical dossier preparation and submission. With local representation in over 30 countries, we ensure your company meets all local requirements efficiently. To learn how we can accelerate your market access, visit https://pureglobal.com, contact us at [email protected], or explore our free AI tools and regulatory database at https://pureglobal.ai.

The US FDA's final order on September 17, 2026, clarifies the partial 510(k) premarket notification exemption for specific AI/ML-driven radiology software. This episode breaks down the practical impact of this decision on manufacturers of computer-aided detection/diagnosis (CADe/CADx) and triage devices. We explain which devices are affected, why the FDA denied a broader exemption, and what the term "partial exemption" means for your regulatory strategy and US market access plans.

Key Questions:

- What did the FDA's September 17, 2026 final order on radiology AI software clarify?

- Which specific types of AI/ML devices, like CADe and CADx, are impacted by this ruling?

- Why did the FDA deny the petition for a broader 510(k) exemption?

- What does a "partial exemption" mean in practice for software developers?

- How does this order affect the US market access strategy for AI-driven radiology tools?

- What are the next steps for regulatory teams managing these devices?

- Does this exemption remove the need for a robust Quality Management System?

- How should companies adjust their timelines and budgets in light of this clarification?

Sources:

- https://www.federalregister.gov/documents/2026/09/17/2026-20123/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-detection-andor

- https://www.fda.gov/medical-devices/cdrh-new-news-and-updates/september-2026-cdrh-new

How Pure Global can help:

Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets like the United States. Our experts develop efficient regulatory strategies and manage technical dossier submissions to streamline FDA clearance for AI/ML software and other devices. We leverage advanced AI tools to accelerate document compilation and ensure compliance, reducing your time to market. Whether you're a startup or a multinational, Pure Global offers the local expertise and technology-driven solutions needed to achieve and maintain market access. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and global device database at https://pureglobal.ai.

China's NMPA has released the world's first product standard for AI-powered Brain-Computer Interface (BCI) medical devices, effective September 1, 2027. This episode breaks down the new technical requirements for the full data lifecycle—from acquisition and processing to storage and cybersecurity. We explore what this means for global manufacturers of AI/ML-enabled devices and outline practical steps for ensuring compliance to access the Chinese market.

Key Questions:

- What is the new NMPA standard for AI-powered BCI medical devices?

- When does this new Chinese standard take effect?

- Which types of medical device manufacturers are impacted by this regulation?

- What are the specific technical requirements for data acquisition and processing?

- How does the standard address AI algorithm validation and transparency?

- What are the cybersecurity and data privacy expectations for BCI devices in China?

- What practical steps should regulatory teams take to prepare for compliance?

- Why is this standard a significant development for the global AI medical device industry?

Sources:

- https://news.cgtn.com/news/2026-09-14/China-releases-world-s-1st-standard-for-AI-powered-BCI-medical-devices-1wO8g4qZzS0/p.html

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including China. We specialize in developing regulatory strategies for innovative AI/ML-enabled devices, preparing technical dossiers that meet stringent NMPA requirements, and navigating complex data privacy and cybersecurity laws. Our combination of local expertise and advanced AI tools helps streamline the submission process, ensuring your novel technology achieves market access efficiently. To learn more, contact us at [email protected], visit https://pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.

China's NMPA issued a notice on September 9, 2026, significantly streamlining the regulatory process for foreign manufacturers to localize the production of imported medical devices. This episode breaks down the key changes, including the ability to leverage original overseas registration materials for domestic submissions. We discuss which companies are affected, the requirements for demonstrating substantial equivalence, and the practical steps regulatory and quality teams should take to capitalize on this new, more efficient pathway to the Chinese market.

Key Questions:

- What is the new NMPA policy for localizing imported medical devices in China?

- How does this change, effective September 9, 2026, affect foreign manufacturers?

- Can overseas clinical and non-clinical data now be used for domestic registration?

- What constitutes 'substantial equivalence' between an imported and a locally produced device?

- Who is eligible to benefit from this streamlined pathway?

- What are the immediate steps regulatory teams should take in response to this notice?

- How does this policy reduce the time and cost of market access in China?

- What documentation is required to prove the localized product is the same as the imported one?

Sources:

- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5_SGrB126Gd-NrbYAjDBPJwKs8J9NizRk5QxnblXLOAp59lcbPlZcTfa0t8G_FeByg5N5EXLrTCc6qSNt0-burNjqHFaCL8gqHH0Bf-Hdxc6I2w7GLcci_nfZPMwj1lqNxPE7cvgrAC_dDl_TUtI2z40ywDYhOBRpFp7hB9hNzh8zfNPA2o6UVKPAsb4oimdssGVc

How Pure Global can help:

Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies. Our local experts in China and advanced AI tools can help your company navigate the NMPA's new localization policy, from assessing your existing dossiers to managing the submission process for domestic registration. We help you leverage this new pathway to accelerate your market presence in China. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

Mexico's health regulator, COFEPRIS, has updated the operational guidelines for Authorized Third Parties (ATPs), effective September 3, 2026. This episode explores the two main changes: the new, standardized four-year validity period for ATP authorizations and the formal separation of administrative versus technical modifications. We discuss how these updates create a more stable and predictable regulatory environment for medical device manufacturers who use the ATP pathway to expedite their market entry into Mexico, and we outline practical steps for regulatory teams to take in response.

Key Questions:

- What are the new COFEPRIS guidelines for Authorized Third Parties (ATPs) that took effect on September 3, 2026?

- How does the new four-year validity period for ATP authorizations impact their stability and reliability?

- What is the new distinction between an administrative and a technical modification for an ATP's authorization?

- Why is this change significant for medical device manufacturers using the ATP pathway in Mexico?

- How can you verify if your ATP partner is compliant with the latest guidelines?

- What should regulatory teams consider when reviewing service agreements with their ATPs?

- How does this update fit into COFEPRIS's broader strategy of regulatory simplification?

- What practical steps can you take to leverage this change for your Mexico market access strategy?

Sources:

- https://mexicobusiness.news/health/news/cofepris-sets-four-year-validity-for-third-party-authorizations

How Pure Global can help:

Pure Global helps MedTech and IVD companies navigate complex regulatory landscapes like Mexico's COFEPRIS system. Our local experts and advanced AI tools streamline market access, from developing a regulatory strategy that leverages pathways like the Authorized Third Party program to compiling and submitting technical dossiers. We provide end-to-end consulting to get your products to market faster and maintain compliance. For more information on how we can accelerate your global expansion, contact us at [email protected] or visit https://pureglobal.com. Be sure to explore our free AI regulatory assistant and global device database at https://pureglobal.ai.

The Saudi Food and Drug Authority (SFDA) has approved its first two locally developed AI-enabled Software as a Medical Device (SaMD) products, 'Dental IQ' and 'SAARIA,' on September 10, 2026. This episode explores the significance of this regulatory milestone, what it reveals about the SFDA's Innovative Medical Devices Pathway, and the key technical and clinical requirements for manufacturers of AI medical software seeking market access in Saudi Arabia.

Key Questions:

- What major regulatory milestone did the SFDA achieve on September 10, 2026?

- How does the approval of 'Dental IQ' and 'SAARIA' impact the Saudi MedTech landscape?

- What does this event signal about the viability of the SFDA's Innovative Medical Devices Pathway?

- What are the likely technical documentation requirements for AI software in Saudi Arabia?

- How should manufacturers prepare their clinical evidence for an SFDA submission?

- Why are algorithm transparency and cybersecurity critical factors for SFDA approval?

- What practical steps can SaMD companies take now to prepare for market entry into Saudi Arabia?

- How does this development affect the broader Gulf Cooperation Council (GCC) market?

Sources:

- https://www.spa.gov.sa/en/N2138048

- https://saudigazette.com.sa/article/645609/SAUDI-ARABIA/SFDA-grants-marketing-authorization-for-2-Saudi-developed-AI-enabled-medical-software-products

How Pure Global can help:

Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, and develop efficient regulatory strategies to minimize costs and delays. Our AI-powered tools help compile and manage technical dossiers for complex products like AI-enabled SaMD, ensuring submissions meet SFDA standards for algorithm validation and clinical evidence. From initial market research to post-market surveillance, we offer end-to-end support to get your innovative products to patients faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.